Niki BioSolutions, Inc. · NASDAQ:NIKI

Niki BioSolutions — Aptorum Group — Investor Presentation (September 2020)

36 slides from Niki BioSolutions's investor presentation, Sep 1, 2020

1. Slide 1: Facilitating Life Science Innovations to Serve Unmet Medical Needs

   Facilitating Life Science Innovations to Serve Unmet Medical Needs CORPORATE PRESENTATION NASDAQ GLOBAL MARKET: APM

2. Slide 2: Disclaimer

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 2 Disclaimer This document includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “f

3. Slide 3: About Aptorum Group

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 3 About Aptorum Group • Established in 2010, focused on current unmet medical needs, including orphan diseases, infectious diseases, metabolic dise

4. Slide 4: Directors, Management and Significant Employees

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 1 Directors, Management and Significant Employees • Over 15 years in global asset management; • US healthcare equity research analyst at Janus Hend

5. Slide 5: Aptorum Team: Consultants and Advisors

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 2 Aptorum Team • Professor of Surgery, School of Medicine, University of Chicago; • Former A sso . Professor at Johns Hopkins University; • M.D., J

6. Slide 6: Current progress of leading pipeline programs and discovery

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 6 Current progress of leading pipeline programs and discovery NDA NDA 1. Refers to the drug’s existing Phase I/II safety data previously conducted

7. Slide 7: Current progress of leading pipeline programs and discovery

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 7 Current progress of leading pipeline programs and discovery

8. Slide 8: Orphan Disease Focus and Selection

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 8 4."35  "$5  Π
   %SVH
   %JTDPWFSZ
   1MBUGPSN
   0SQIBO
   %JTFBTF
   'PDVT
   BOE
   4FMFDUJPO Life threatening disease High unmet need IP protection Market size

9. Slide 9: Pipeline Workflow

   For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome l%QR[TKIJV  #RVQTWO)TQWR.KOKVGF 9 4."35  "$5 Π
   
   1JQFMJOF
   8PSLýPX 2 ,600 FDA - approved small molecule drugs • Life threatening disease • Lack of effective treatment • Large

10. Slide 10: SACT-1 neuroblastoma market overview

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 10 4"$5  
    OFVSPCMBTUPNB 
    NBSLFU
    PWFSWJFX • ~700 cases of high risk neuroblastoma (NB) patients each year in the US 3 and we estimated EU has 1.

11. Slide 11: In vitro drug activity against neuroblastoma cell lines

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited  In vitro drug activity against neuroblastoma cell lines • SACT - 1’s potential action against neuroblastoma might be patentable • We find that i

12. Slide 12: Synergistic effect of SACT-1 in combination with standard treatment

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited  Synergistic effect of SACT - 1 in combination with standard treatment • Synergistic effect observed for SACT - 1 in combination with standard tr

13. Slide 13: SACT-1: Combination study with standard chemotherapy in vivo model

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited  SACT - 1: Combination study with standard chemotherapy in vivo model ** Unpaired Student’s T - test, p<0.01, n=8 (based on data observed over in

14. Slide 14: SACT-1: safety & tolerability

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 14 SACT - 1: safety & tolerability ‡ %JE
    OPU
    TIPX
    HFOPUPYJD
    QPUFOUJBM
    FWFO
    BU
    UIF
    IJHIFTU
    GFBTJCMF
    DPODFOUSBUJPO
    EPTF
    JO
    WJUSP
    BOE
    JO
    WJWP ‡ *

15. Slide 15: Executive summary: Acticule projects

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 15 Executive summary: Acticule projects • Aptorum's lead program ALS - 4 is an anti - virulent, non - bactericidal drug candidate for Staphylococcu

16. Slide 16: ALS-4: Market Overview

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 16 ALS - 4: Market Overview ‡ *O
    
    .FSDLhT
    BDRVJTJUJPO
    PG
    $VCJTU
    1IBSNBDFVUJDBMT
    B
    MBSHF
    EFWFMPQFS
    PG
    BOUJCJPUJDT
    GPS
    64%
     CO  ‡ *O
    

17. Slide 17: Market Approved Drugs for MRSA Infections

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 17 Market Approved Drugs for MRSA Infections 'SFRVFOUMZ
    QSFTDSJCFE
    BOUJCJPUJDT
    GPS
    .34"
    JOGFDUJPOT  Product (Company) Antibiotic Class Indication(

18. Slide 18: ALS-4: Addressing the Shortfall of Vancomycin

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 18 ALS - 4: Addressing the Shortfall of Vancomycin • Generic antibiotic that is the most frequently prescribed for MRSA - suspected infections 1,2

19. Slide 19: ALS-4: Value Proposition

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited Antibiotics  ALS - 4: Value Proposition • Antibiotic resistance in S. aureus has been discovered in most prescribed antibiotics for MRSA 1 • Broa

20. Slide 20: Mechanism of Action: Staphyloxanthin of Staphylococcus aureus

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 20 Mechanism of Action: Staphyloxanthin of Staphylococcus aureus The above diagram summarizes the mechanism of action by Staphyloxanthin of Staphyl

21. Slide 21: Mechanism of Action - ALS-4 on Staphyloxanthin Synthesis

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 21 Mechanism of Action - ALS - 4 on Staphyloxathin Synthesis The description of ALS - 4 and related conclusory statements on ALS - 4 on this slide

22. Slide 22: ALS-4: oral formulation treatment in an MRSA survival study

    (QTKNNWUVTCVKXGRWTRQUGUQPN[6JGTGKUPQIWCTCPVGGQHCP[RTQLGEVDGKPIEQORNGVGFQTJCXKPICURGEKHKEQWVEQOG © Copyright 2020 Aptorum Group Limited 22 ALS - 4: oral formulation treatment in an MRSA survival study • A lethal dose (10 9 CFU) of MRSA was introduced through the tail vein • ALS - 4

23. Slide 23: ALS-4: oral formulation treatment in a non-lethal bacteremia model

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 23 "-4   
    PSBM
    GPSNVMBUJPO
    USFBUNFOU
    JO
    B
    OPO  MFUIBM
    CBDUFSFNJB
    NPEFM • Rats were challenged with a non - lethal dose (10 7 CFU) of MRSA th

24. Slide 24: ALS-4: Oral administration in a MRSA non-lethal bacteraemia mouse model

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 24 ALS - 4: Oral administration in a MRSA non - lethal bacteraemia mouse model ALS - 4 ( Compound IM032) with increasing dose range shows a statist

25. Slide 25: ALS-4: Oral administration in a MRSA mouse skin wound infection model

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 25 ALS - 4: Oral administration in a MRSA mouse skin wound infection model The results shown in this slide are based on Aptorum's internal (in vitr

26. Slide 26: ALS-1: Targeting a Novel Druggable Target for Influenza A

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 26 ALS - 1: Targeting a Novel Druggable Target for Influenza A • NP is the most abundantly expressed protein during the course of an infection 1 .

27. Slide 27: Claves Executive Summary

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited  Claves Executive Summary • We live in constant symbiosis with our gut bacteria, and dysbiosis can be the cause to numerous diseases 1 Human Micr

28. Slide 28: Claves Platform and CLS-1: Value Proposition

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 28 Claves Platform and CLS - 1: Value Proposition CLS - 1 • Identified specific microbiota metabolite linked to obesity • Novel therapeutic that ph

29. Slide 29: Mechanism of Action: Metabolite 1 and obesity

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 29 Mechanism of Action Metabolite 1 produced by the microbiome and its link to obesity • High - fat diet in rats increased levels of metabolite 1 i

30. Slide 30: CLS-1: Market Overview

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 30 CLS - 1: Market Overview • Boehringer Ingelheim committed up to USD 300m to work with Gubra on obesity treatments Recent Deals in Obesity Treatm

31. Slide 31: CLS-1: Efficacy in a Mouse Model

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 31 CLS - 1: Efficacy in a Mouse Model The above data are based on Aptorum's internal tests and has not yet been verified by clinical trials or thir

32. Slide 32: NLS-2: Executive Summary

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 32 NLS - 2: Executive Summary • NLS - 2 is a dietary supplement for the relief of menopausal symptoms. • The bioactive component of NLS - 2 is DOI,

33. Slide 33: APPENDIX

    APPENDIX

34. Slide 34: Income Statement Summary (U.S. GAAP)

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 34 Income Statement Summary (U.S. GAAP) 1 Notes: 1 . The following slide contains selected information for the Company's income statement . Please

35. Slide 35: Selected Balance Sheet Items (U.S. GAAP)

    For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome © Copyright 2020 Aptorum Group Limited 35 Selected Balance Sheet Items (U.S. GAAP) 1 Notes: 1. The following slide contains selected information for the Company's balance sheets. Please

36. Slide 36: T +44 80929299 F +44 39288277

    T +44 020 80929299 F +44 020 39288277

Aptorum Group — Investor Presentation (September 2020) on 6ix